101results about How to "Reducing treatment" patented technology

In one embodiment, the present invention provides a method of reducing the viscosity of a viscosified treatment fluid comprising contacting the viscosified treatment fluid with an acid generated from an orthoester composition that comprises an orthoester. In another embodiment, the present invention provides a method of reducing the pH of a viscosified treatment fluid comprising providing an orthoester composition that comprises an orthoester; contacting the viscosified treatment fluid with the orthoester composition; allowing the orthoester to generate a generated acid; and allowing the generated acid to at least partially reduce the pH of the viscosified treatment fluid. Embodiments of fracturing and gravel packing methods also are disclosed.

A connecting means adapted to fix or release a first element (4) and a second element (5) includes a locking pin (1) which is moveable to remote activation means between a locked position. In which leg (8) expends wall (9) into recess (10), and an unlocked position. The remote activation means may be magnetic, electro-magnetic or any other suitable means. A method of fixing or releasing first and second elements by remote activation means is also disclosed. The invention further provides a first element having first means (166) adapted to cooperate with second means (165) on a second element to facilitate connection of the first and second elements. A method of manufacturing the first element includes the steps of depositing discrete amounts of setable material on a surface of the first element and inverting the element to permit the material to set under the influence of gravity. A method of reducing the spacing between first and second elements by remote activation means is also disclosed.

The invention relates to a method and apparatus for predicting a sudden heart abnormality for an individual patient. In order to provide a prediction mechanism that is suitable for acute care, three sub-indices are determined based on medical data obtained from the patient. The first sub-index indicates the level of deterministic chaos in the heart rate variability of the patient, the second sub-index indicates the energy level in the myocardium of the patient, and the third sub-index indicates the degree of ventricular arrhythmia of the patient. Based on the first, second, and third sub-indices, at least one overall risk index is then determined, the overall risk index indicating the risk level of a sudden heart abnormality for the patient.

A bracket for orthodontic use has a base plate, a tie wing and an arch wire fitting slot. More specifically, a pair of tie wings having a pair of long and short wing pieces, i.e., a long piece and a short piece, are erected on the rectangular base plate and spaced apart, and the arch wire fitting slot is formed by the spaced apart portion. A pair of wing pieces of the tie wing are provided to project in the vertical direction with distal ends directed downward, and constituted the wing pieces include a long piece and a short piece. A recessed guide groove is provided in a vicinity of an end of the long piece.

Disclosed are methods for the treatment and / or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1β antibody or fragment thereof.

A connecting means adapted to releasably fix or release a first element (4) and a second element (5) includes a locking pin (1) which is moveable by remote activation means between a locked position, in which leg (8) expands wall (9) into recess (10), and an unlocked position. The remote activation means may be magnetic, electromagnetic or any other suitable means. There is no permanent material connection between the pin (1) and the remote activation means. A method of fixing or releasing first and second elements by remote activation means is also disclosed. The invention further provides an embodiment where the first element is a first panel and the second element is a second panel. The first panel has means (166 or 169) which co-ordinate with means (165 or 170) on the second panel. A method of manufacturing the first element includes the steps of depositing discrete amounts of setable material on a surface of the first element and inverting the element to permit the material to set under the influence of gravity. A method of reducing the spacing between first and second elements by remote activation means is also disclosed.

A continuous simulated moving bed chromatographic focusing process is disclosed for separating and concentrating multiple components from a complex mixture. Said process comprises a number of zones that are connected in series. An eluent flows unidirectionally along the zones and decreases its desorption strength by sequential dilutions zone after zone. Each zone is detachably installed with a chromatographic column and the columns are periodically relocated one zone upstream. Multiple components of a sample are introduced into a downstream zone, absorbed on the column in the zone, brought zone by zone upstream by column relocations, and selectively desorbed from different zones to get separation. A component desorbed from one zone is reabsorbed by the column in the adjacent downstream zone and is again brought back to said zone by column relocation. Said component is thus retained between said zone and said adjacent downstream zone and is accumulated by continuous sample feeding and repeatedly column relocation.

The present invention relates to methods of improving a treatment outcome comprising administering a heat shock protein (HSP) preparation or an α-2-macroglobulin (α2M) preparation with a non-vaccine treatment modality. In particular, an HSP preparation or an α2M preparation is administered in conjunction with a non-vaccine treatment modality for the treatment of cancer or infectious diseases. In the practice of the invention, a preparation comprising HSPs such as but not limited to, hsp70, hsp90 and gp96 alone or in combination with each other, noncovalently or covalently bound to antigenic molecules or α2M, noncovalently or covalently bound to antigenic molecules is administered in conjunction with a non-vaccine treatment modality.